Posted by Michael Wonder on 18 Mar 2019
Praluent (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease
15 March 2019 - Approval is based on ODYSSEY OUTCOMES trial of 18,924 patients who recently suffered an acute coronary syndrome such as a heart attack.
The European Commission has approved a new indication for Praluent (alirocumab), to reduce cardiovascular risk in adults with established atherosclerotic CV disease by lowering low-density lipoprotein cholesterol levels as an adjunct to correction of other risk factors.
